Back to search

Peptide record

TPDB02713

Antibacterial Anticancer Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB02713
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and CancerPPD 2.0, with an available 3D structural model.
Sequence
VRRFPWYYPFLRR
Physicochemical Analysis
C92H130N26O16
ANDCEQGHIKMST
R
1856.21
11.94
4
0
7
+4
-2.34
-0.854
52.31
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
8480
456.85
2
Residue Composition
number
0
A
4
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
0
K
0
M
2
F
2
P
0
S
0
T
1
W
2
Y
1
V
Amino Acid Distribution
A: 0 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 0 M: 0 F: 2 P: 2 S: 0 T: 0 W: 1 Y: 2 V: 1
Chemical Descriptors
13
C92H130N26O16
1856.21
11.94
+4
-2.34
-0.854
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
Toxicity
>=65 µM
Cytotoxic
IC50 | >=65 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. | Biochim Biophys Acta | 2020
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
>=65 µM
Hemolytic Cytotoxic
50% Hemolysis | >=65 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. | Biochim Biophys Acta | 2020
Evidence 3 Activity

Activity

IC50
Toxicity
65 µM
Hemolytic Cytotoxic
Hemolytic_activity: RBC: IC50 ≥ 65 µM | Cytotoxicity: PBMC: IC50 ≥ 65 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochim Biophys Acta Biomembr. 2020 Aug 1 1862(8):183228.